Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2026 06:52 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 08, 2026 06:31 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 08, 2026 06:30 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial
April 08, 2026 08:00 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
March 10, 2026 16:05 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal...
February 25, 2026 08:00 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell...
February 24, 2026 08:00 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible...
February 19, 2026 08:00 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible...
January 21, 2026 08:00 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible...
November 12, 2025 07:20 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease